GeneDx Reports Preliminary FY25 Revenue of $427M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy WGS?
Reports preliminary FY25 revenue $427M, consensus $427.04M. "In 2025, GeneDx continued its journey of transforming the standard of pediatric care by accelerating the use of genomics to the earliest moment families need answers. In doing so, we delivered on our commitment to high growth and profitability, thanks to the relentless commitment of our team," said Katherine Stueland, president and CEO of GeneDx. "As we enter 2026, GeneDx is accelerating. Powered by GeneDx Infinity - the world's largest rare disease genomic dataset - and our AI-driven platform, we are positioned for durable, profitable growth over the next several years while accelerating diagnoses for patients around the world. We are expanding - scaling across care settings, growing internationally, deepening partnerships across the healthcare ecosystem, and investing in the data and expertise that will define the next era of precision medicine - to make earlier diagnosis the norm, not the exception. Our growth is purposeful, and it is inseparable from our impact."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WGS
Wall Street analysts forecast WGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WGS is 171.43 USD with a low forecast of 155.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 84.080
Low
155.00
Averages
171.43
High
200.00
Current: 84.080
Low
155.00
Averages
171.43
High
200.00
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Global Payments Inc (GPN) Options Trading Volume Hits 1.6 Million Shares
- Active Options Trading: Global Payments Inc (GPN) saw options trading volume of 16,123 contracts today, representing approximately 1.6 million shares, which is about 53% of its average daily trading volume of 3 million shares over the past month, indicating strong market interest in its future performance.
- High Volume Analysis: Notably, the $60 strike put option for GPN has seen particularly high activity with 7,070 contracts traded today, representing around 707,000 underlying shares, reflecting investor expectations regarding potential downside risks for the stock.
- GeneDx Options Activity: Concurrently, GeneDx Holdings Corp (WGS) has recorded an options trading volume of 2,883 contracts today, equivalent to approximately 288,300 shares, which constitutes 52% of its average daily trading volume of 554,545 shares over the past month, indicating investor focus on its market performance.
- Bullish Call Option Trend: For WGS, the $150 strike call option has seen a trading volume of 1,512 contracts today, representing about 151,200 shares, suggesting a bullish outlook among investors regarding its future price potential.
See More
ARK Invest Deepens AI Chip and Gene Editing Investments, Sells 86K Tesla Shares
- AI Infrastructure Boost: ARK Invest increased positions in semiconductor companies like AMD, Broadcom, and TSMC, signaling strong confidence in the infrastructure for AI workloads, which is expected to drive long-term growth for these firms.
- Gene Editing Investments: The firm added 196K shares of Intellia Therapeutics and 49K shares of 10x Genomics, continuing to focus on next-generation sequencing and in vivo gene editing, aiming to capture innovative opportunities in the biotech sector.
- Autonomous Driving Focus: ARK invested in companies like WeRide and Pony AI in the autonomous driving and robotics space, reinforcing its strategic positioning in future transportation technologies, which is likely to enhance portfolio diversity and potential returns.
- Trimmed Mature Tech Holdings: ARK sold over 86K shares of Tesla worth more than $37 million and reduced stakes in Unity Software, reflecting a cautious stance on mature tech companies that may impact short-term stock performance.
See More
GeneDx Holdings Corp (WGS) Options Volume Hits 4,198 Contracts, 109.9% of Average
- Active Options Trading: GeneDx Holdings Corp's options volume reached 4,198 contracts today, representing approximately 419,800 underlying shares, indicating a trading activity level of 109.9% of its average daily volume over the past month.
- Put Option Focus: Notably, the $100 strike put option expiring on February 20, 2026, saw 705 contracts traded today, representing about 70,500 underlying shares, reflecting market attention at this price level.
- Alphabet Options Activity: Concurrently, Alphabet Inc's options trading volume stood at 320,179 contracts, equivalent to approximately 32.0 million underlying shares, reaching 108.8% of its average daily volume over the past month, indicating strong market engagement.
- High Interest Call Option: Among Alphabet's options, the $330 strike call option expiring on January 16, 2026, recorded a trading volume of 23,994 contracts, representing around 2.4 million underlying shares, suggesting investor expectations for future price increases.
See More
GeneDx Reports $427M Revenue for 2025, 41% YoY Growth
- Significant Revenue Growth: GeneDx reported approximately $427M in revenue for 2025, aligning with market expectations and reflecting a 41% year-over-year increase, which reinforces the company's strong position in the genetic testing market.
- Robust Genomic Revenue: The exome and genome revenue for 2025 reached approximately $360M, marking a 54% year-over-year growth, exceeding prior guidance of 53% to 55%, indicating sustained expansion in high-growth areas.
- Increased Test Volume: The total volume of exome and genome test results for 2025 was 97,271, representing a 30.5% year-over-year increase, surpassing the company's prior guidance of at least 30%, reflecting strong customer demand recovery.
- Optimistic Future Outlook: GeneDx anticipates revenue for 2026 to be between $540M and $555M, with exome and genome revenue expected to grow by 33% to 35%, demonstrating the company's confidence in future growth and a positive market outlook.
See More
GeneDx Partners with Komodo Health to Build Comprehensive Rare Disease Dataset
- Strategic Partnership: GeneDx has formed a strategic partnership with Komodo Health to leverage Komodo's Healthcare Map®, creating the most comprehensive longitudinal dataset for rare diseases, enhancing visibility into diagnosis, management, and treatment.
- Data Scale: GeneDx Infinity™ is the world's largest rare disease genomic dataset, built on over 2.5 million genetic tests and more than 7 million phenotypic data points, with over half of individuals representing non-European ancestry, showcasing exceptional diversity and representation.
- Accelerating Innovation: This collaboration is set to drive biopharma innovation, with GeneDx Infinity expected to generate 30% more exome and genome data in 2025 than in the previous 24 years combined, providing a richer evidence base for rare disease research.
- Privacy Protection: All data integrations and analyses will utilize de-identified, privacy-preserving methodologies to ensure regulatory compliance and protect patient confidentiality, thereby maintaining ethical standards while advancing research.
See More
GeneDx Appoints Linda Genen as Chief Medical Officer to Enhance Clinical Strategy
- Executive Appointment: GeneDx Holdings Corp. announced the appointment of Linda Genen as Chief Medical Officer, who will oversee Medical and Clinical Affairs, aiming to enhance the company's clinical strategy to meet the growing demand for rare disease diagnostics.
- Extensive Experience: Genen brings a wealth of experience in clinical practice, payer strategy, innovation, and maternal-infant health, having previously served as Chief Medical Officer at ProgenyHealth, where she led clinical strategy, which is expected to provide GeneDx with new insights and expertise.
- Strategic Impact: This appointment not only strengthens GeneDx's leadership in the rare disease sector but may also drive future business growth by optimizing clinical processes and improving patient care quality.
- Industry Context: In the increasingly competitive rare disease diagnostics market, Genen's addition will help GeneDx better navigate market challenges and seize emerging opportunities.
See More
Global Payments Inc (GPN) Options Trading Volume Hits 1.6 Million Shares
- Active Options Trading: Global Payments Inc (GPN) saw options trading volume of 16,123 contracts today, representing approximately 1.6 million shares, which is about 53% of its average daily trading volume of 3 million shares over the past month, indicating strong market interest in its future performance.
- High Volume Analysis: Notably, the $60 strike put option for GPN has seen particularly high activity with 7,070 contracts traded today, representing around 707,000 underlying shares, reflecting investor expectations regarding potential downside risks for the stock.
- GeneDx Options Activity: Concurrently, GeneDx Holdings Corp (WGS) has recorded an options trading volume of 2,883 contracts today, equivalent to approximately 288,300 shares, which constitutes 52% of its average daily trading volume of 554,545 shares over the past month, indicating investor focus on its market performance.
- Bullish Call Option Trend: For WGS, the $150 strike call option has seen a trading volume of 1,512 contracts today, representing about 151,200 shares, suggesting a bullish outlook among investors regarding its future price potential.
See More
ARK Invest Deepens AI Chip and Gene Editing Investments, Sells 86K Tesla Shares
- AI Infrastructure Boost: ARK Invest increased positions in semiconductor companies like AMD, Broadcom, and TSMC, signaling strong confidence in the infrastructure for AI workloads, which is expected to drive long-term growth for these firms.
- Gene Editing Investments: The firm added 196K shares of Intellia Therapeutics and 49K shares of 10x Genomics, continuing to focus on next-generation sequencing and in vivo gene editing, aiming to capture innovative opportunities in the biotech sector.
- Autonomous Driving Focus: ARK invested in companies like WeRide and Pony AI in the autonomous driving and robotics space, reinforcing its strategic positioning in future transportation technologies, which is likely to enhance portfolio diversity and potential returns.
- Trimmed Mature Tech Holdings: ARK sold over 86K shares of Tesla worth more than $37 million and reduced stakes in Unity Software, reflecting a cautious stance on mature tech companies that may impact short-term stock performance.
See More
GeneDx Holdings Corp (WGS) Options Volume Hits 4,198 Contracts, 109.9% of Average
- Active Options Trading: GeneDx Holdings Corp's options volume reached 4,198 contracts today, representing approximately 419,800 underlying shares, indicating a trading activity level of 109.9% of its average daily volume over the past month.
- Put Option Focus: Notably, the $100 strike put option expiring on February 20, 2026, saw 705 contracts traded today, representing about 70,500 underlying shares, reflecting market attention at this price level.
- Alphabet Options Activity: Concurrently, Alphabet Inc's options trading volume stood at 320,179 contracts, equivalent to approximately 32.0 million underlying shares, reaching 108.8% of its average daily volume over the past month, indicating strong market engagement.
- High Interest Call Option: Among Alphabet's options, the $330 strike call option expiring on January 16, 2026, recorded a trading volume of 23,994 contracts, representing around 2.4 million underlying shares, suggesting investor expectations for future price increases.
See More
GeneDx Reports $427M Revenue for 2025, 41% YoY Growth
- Significant Revenue Growth: GeneDx reported approximately $427M in revenue for 2025, aligning with market expectations and reflecting a 41% year-over-year increase, which reinforces the company's strong position in the genetic testing market.
- Robust Genomic Revenue: The exome and genome revenue for 2025 reached approximately $360M, marking a 54% year-over-year growth, exceeding prior guidance of 53% to 55%, indicating sustained expansion in high-growth areas.
- Increased Test Volume: The total volume of exome and genome test results for 2025 was 97,271, representing a 30.5% year-over-year increase, surpassing the company's prior guidance of at least 30%, reflecting strong customer demand recovery.
- Optimistic Future Outlook: GeneDx anticipates revenue for 2026 to be between $540M and $555M, with exome and genome revenue expected to grow by 33% to 35%, demonstrating the company's confidence in future growth and a positive market outlook.
See More
GeneDx Partners with Komodo Health to Build Comprehensive Rare Disease Dataset
- Strategic Partnership: GeneDx has formed a strategic partnership with Komodo Health to leverage Komodo's Healthcare Map®, creating the most comprehensive longitudinal dataset for rare diseases, enhancing visibility into diagnosis, management, and treatment.
- Data Scale: GeneDx Infinity™ is the world's largest rare disease genomic dataset, built on over 2.5 million genetic tests and more than 7 million phenotypic data points, with over half of individuals representing non-European ancestry, showcasing exceptional diversity and representation.
- Accelerating Innovation: This collaboration is set to drive biopharma innovation, with GeneDx Infinity expected to generate 30% more exome and genome data in 2025 than in the previous 24 years combined, providing a richer evidence base for rare disease research.
- Privacy Protection: All data integrations and analyses will utilize de-identified, privacy-preserving methodologies to ensure regulatory compliance and protect patient confidentiality, thereby maintaining ethical standards while advancing research.
See More
GeneDx Appoints Linda Genen as Chief Medical Officer to Enhance Clinical Strategy
- Executive Appointment: GeneDx Holdings Corp. announced the appointment of Linda Genen as Chief Medical Officer, who will oversee Medical and Clinical Affairs, aiming to enhance the company's clinical strategy to meet the growing demand for rare disease diagnostics.
- Extensive Experience: Genen brings a wealth of experience in clinical practice, payer strategy, innovation, and maternal-infant health, having previously served as Chief Medical Officer at ProgenyHealth, where she led clinical strategy, which is expected to provide GeneDx with new insights and expertise.
- Strategic Impact: This appointment not only strengthens GeneDx's leadership in the rare disease sector but may also drive future business growth by optimizing clinical processes and improving patient care quality.
- Industry Context: In the increasingly competitive rare disease diagnostics market, Genen's addition will help GeneDx better navigate market challenges and seize emerging opportunities.
See More
